There have been three B cell–targeted therapies evaluated in SS: epratuzumab, an anti-CD22 monoclonal antibody, rituximab, an anti-CD20 monoclonal antibody, and Belimumab, an anti-BAFF monoclonal antibody [75,76,77]. Here, TNFSF13B is linked to synovial sarcoma.